BeiGene | Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

⟵ Back to Search Results

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Beigene Study ID

BGB-290-302

ClinicalTrials.gov ID

NCT03519230

China Drug Trials ID

CTR20171666

Sex: Female

Age: 18 Years / N/A

No Study Documents

Sex: Female

Age: 18 Years / N/A

No Study Documents